Trial · NCT00423319
Adverse events372
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 372
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Procedural pain | Injury, poisoning and procedural complications | Apixaban, 2.5 mg BID + Placebo | 421 | 2,673 | |
| other | Procedural pain | Injury, poisoning and procedural complications | Enoxaparin, 40 mg QD + Placebo | 426 | 2,659 | |
| other | Dizziness | Nervous system disorders | Apixaban, 2.5 mg BID + Placebo | 185 | 2,673 | |
| other | Dizziness | Nervous system disorders | Enoxaparin, 40 mg QD + Placebo | 154 | 2,659 | |
| other | Insomnia | Psychiatric disorders | Apixaban, 2.5 mg BID + Placebo | 138 | 2,673 | |
| other | Insomnia | Psychiatric disorders | Enoxaparin, 40 mg QD + Placebo | 132 | 2,659 | |
| other | Tachycardia | Cardiac disorders | Apixaban, 2.5 mg BID + Placebo | 123 | 2,673 | |
| other | Tachycardia | Cardiac disorders | Enoxaparin, 40 mg QD + Placebo | 137 | 2,659 | |
| other | Oedema peripheral | General disorders | Apixaban, 2.5 mg BID + Placebo | 156 | 2,673 | |
| other | Oedema peripheral | General disorders | Enoxaparin, 40 mg QD + Placebo | 141 | 2,659 | |
| other | Pyrexia | General disorders | Apixaban, 2.5 mg BID + Placebo | 236 | 2,673 | |
| other | Pyrexia | General disorders | Enoxaparin, 40 mg QD + Placebo | 242 | 2,659 | |
| other | Constipation | Gastrointestinal disorders | Apixaban, 2.5 mg BID + Placebo | 318 | 2,673 | |
| other | Constipation | Gastrointestinal disorders | Enoxaparin, 40 mg QD + Placebo | 364 | 2,659 | |
| other | Hypotension | Vascular disorders | Apixaban, 2.5 mg BID + Placebo | 259 | 2,673 | |
| other | Hypotension | Vascular disorders | Enoxaparin, 40 mg QD + Placebo | 262 | 2,659 | |
| other | Nausea | Gastrointestinal disorders | Apixaban, 2.5 mg BID + Placebo | 485 | 2,673 | |
| other | Nausea | Gastrointestinal disorders | Enoxaparin, 40 mg QD + Placebo | 529 | 2,659 | |
| other | Urinary retention | Renal and urinary disorders | Apixaban, 2.5 mg BID + Placebo | 174 | 2,673 | |
| other | Urinary retention | Renal and urinary disorders | Enoxaparin, 40 mg QD + Placebo | 152 | 2,659 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00423319/events